Inhibitory effects of polyphenol compounds on lipid peroxidation caused by antipsychotics (haloperidol and amisulpride) in human plasma in vitro

References

• Abdalla DSP, Manteiro HP, Olivera JAC, Bechara EJ. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients. Clin Chem 1986; 32: 805–807
   PubMed Web of Science ®Google Scholar
• Allebeck P. Schizophrenia: A life-shortening illness. Schizophr Bull 1989; 15: 81–89
   PubMed Web of Science ®Google Scholar
• Bergemann N, Kopitz J, Kress KR, Frick A. Plasma amisulpride levels in schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol 2004; 14: 245–250
   PubMed Web of Science ®Google Scholar
• Berstein HG, Bogerts B, Keilhoff G. The many faces of nitric oxide in schizophrenia. A review. Schizophr Res 2005; 78: 69–86
   PubMedGoogle Scholar
• Dakhale G, Khanzode S, Saoji A, Khobragade L, Turankar A. Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 2004; 49: 205–209
   PubMed Web of Science ®Google Scholar
• Dietrich-Muszalska A. Evaluation of the effects of different concentrations of risperidone, corresponding to the drug doses used in treatment of schizophrenic patients, on lipid peroxidation in plasma and blood platelets at in vitro studies. Psychiatr Psychol Klin 2004; 4: 215–223
   Google Scholar
• Dietrich-Muszalska A. The impact of different concentrations of clozapine on changes of lipid peroxidation in human plasma – in vitro studies. Psychiatr Psychol Klin 2005; 1: 18–25
   Google Scholar
• Dietrich-Muszalska, A, Kontek, B. 2007. Lipid peroxidation in patients with schizophrenia. Abstracts of the XIII Conference of Polish Biophysics Society. Curr Top Biophy. B-28
   Google Scholar
• Dietrich-Muszalska A, Olas B. Isoprostanes as indicators of oxidative stress in schizophrenia. World J Biol Psychiatry 2007; 14: 1–6
   Google Scholar
• Dietrich-Muszalska, A, Olas, B. Modifications of blood platelet proteins of patients with schizophrenia. Platelets 2008; 1–7, (in press)
   PubMedGoogle Scholar
• Dietrich-Muszalska A, Rabe-Jablonska J, Zgirski A. The effects of olanzapine (Zolafren) on lipid peroxidation in human blood platelets and plasma: in vitro studies. Psychiatr Psychol Klin 2004; 4: 13–19
   Google Scholar
• Dietrich-Muszalska A, Olas B, Rabe-Jablonska J. Oxidative stress in blood platelets from schizophrenic patients. Platelets 2005; 16: 386–391
   PubMed Web of Science ®Google Scholar
• Dietrich-Muszalska, A, Olas, B, Glowacki, R, Bald, E. Oxidative/nitrative modifications of plasma proteins and thiols from patients with schizophrenia. Neuropsychobiology, (in press)
   Google Scholar
• Gama CS, Salvador M, Andreazza AC, Kapczinski F, Silva Belmote-De-Abreu P. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia; a study of patients treated with a haloperidol or clozapine. Prog Neuropsychopharmacol 2006; 30: 512–515
   Google Scholar
• Horrobin DF. Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostaglandins Leukotr Esent Fatty Acids 1996; 55: 3–7
   PubMed Web of Science ®Google Scholar
• Horrobin DF, Manku MS, Hillman H, Iain A, Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biol Psychiatry 1991; 30: 795–805
   PubMed Web of Science ®Google Scholar
• Jeding I, Evans PJ, Akanmu D, Dexter D, Spencer JD, Arunoma OI, et al. Characterization of the potential antioxidants andpro-oxidant actions of some neuroleptic drugs. Biochem Pharmacol 1995; 49: 359–365
   PubMed Web of Science ®Google Scholar
• Kropp S, Kern V, Lange K, Degner D, Hajak G, Kornhuber J, et al. Oxidative stress during treatment with first- and second-generation antipsychotics. J Neuropsych 2005; 17: 227–231
   Google Scholar
• Li HC, Chen QZ, Ma Y, Zhou JF. Imbalanced free radicals and antioxidant defense systems in schizophrenia: a comparative study. J Zhejian Univ Sci B 2006; 12: 981–986
   Google Scholar
• Lohr JB, Kuczenski R, Bracha HS, Moir M, Jeste DV. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 1990; 28: 535–539
   PubMed Web of Science ®Google Scholar
• Müller MJ, Regenbogen B, Härtter S, Eich FX, Hiemke Ch. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. J Psychiatr Res 2007; 41: 673–679
   PubMed Web of Science ®Google Scholar
• Naidu PS, Kulkarni SK. Quercetin, a bioflavonoid, reverses haloperidol-induced catalepsy. Methods Find Exp Clin Pharmacol 2004; 26: 323–326
   PubMedGoogle Scholar
• Olas B, Wachowicz B. Resveratrol, a phenolic antioxidant with effects on blood platelet functions. Platelets 2005; 16: 251–260
   PubMed Web of Science ®Google Scholar
• Pall HS, Williams AC, Blake DR, Lunec J. Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines. Lancet 1987; 2: 596–599
   PubMed Web of Science ®Google Scholar
• Parikh V, Khan MM, Mahadik SP. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 2003; 37: 43–51
   PubMed Web of Science ®Google Scholar
• Peet M, Laugharne J, Rangarajan N, Reynolds GP. Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. Int Clin Psychopharmacol 1993; 8: 151–153
   PubMed Web of Science ®Google Scholar
• Reddy R, Sahebarao MP, Mukherjee S, Murthy JN. Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biol Psychiatry 1991; 30: 409–412
   PubMed Web of Science ®Google Scholar
• Reddy RD, Yao JK. Free radical pathology in schizophrenia: a review. Prostaglandins Leukotrienes Essent Fatty Acids 1996; 55: 33–34
   PubMed Web of Science ®Google Scholar
• Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. J. Neurochem 1998; 71: 1002–1012
   PubMed Web of Science ®Google Scholar
• Seol IW, Kuo NY, Kim KM. Effects of dopaminergic drugs on the mast cell degarulation and nitrix oxide generation in RAW 264.7 cells. Arch Pharm Res 2004; 27: 94–98
   PubMedGoogle Scholar
• Srivastava N, Barthwal MK, Dalal PK, Agarwal AK, Nag D, Srimal RC, et al. Nitrite content and antioxidant enzymes levels in the blood of schizophrenic patients. Psychopharmacology 2001; 158: 140–145
   PubMed Web of Science ®Google Scholar
• Taylor D, Paton C, Kerwin R. The South London and Maudsley NHS Trust. Prescribing guidelines7th ed. Martin Dunitz, Taylor & Francis Group, London and New York 2003
   Google Scholar
• Van Kammen DP, Yao JK, Goetz K. Polyunsaturated fatty acids, prostaglandins, and schizophrenia. Ann NY Acad Sci 1989; 559: 411–423
   PubMedGoogle Scholar
• Wachowicz B. Adenine nucleotides in thrombocytes of birds. Cell Biochem Funct 1984; 2: 167–170
   PubMed Web of Science ®Google Scholar
• Yao JK, Reddy R, Mcelhinny LG, Van Kammen DP. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res 1998; 32: 1–8
   PubMed Web of Science ®Google Scholar
• Yao JK, Leonard S, Reddy R. Membrane phospholipids abnormalities in portmorten brains from schizophrenic patients. Schizophr Res 2000; 42: 7–17
   PubMed Web of Science ®Google Scholar
• Yao JK, Reddy R, Mcelhinny LG, Van Kammen DP. Oxidative damage and schizphrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001; 15: 287–310
   PubMed Web of Science ®Google Scholar
• Young J, Mckinney SB, Ross BM, Wahle KW, Boyle SP. Biomarkers of oxidative stress in schizophrenic and control subjects. Prostaglandins Leukot Essent Fatty Acids 2007; 76: 73–85
   PubMed Web of Science ®Google Scholar
• Zhang XY, Tan YL, Cao LY, Wu GY, Xu Q, Shen Y, et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res 2006; 81: 291–300
   PubMed Web of Science ®Google Scholar